Aravive to Participate in William Blair’s Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success Being Held July 18, 2023

Rhea-AI Summary

Aravive, Inc. announced that its CEO, Gail McIntyre, will be participating in a fireside chat at the William Blair Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success on July 18, 2023. The event will be held virtually and a replay will be available for 7 days.

HOUSTON, July 14, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer will be participating in a fireside chat at the William Blair Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success being held virtually on July 18, 2023.

William Blair’s Innovator Series: Transitioning Biotech Breakthroughs to Commercial Success
Format:	Fireside Chat with Aravive (ARAV)
Date/Time:	Tuesday, July 18, 2023 at 12:00-12:45 PM ET
Host:	Andy Hsieh, Ph.D., Biotech Research Analyst, William Blair
Presenter:	Gail McIntyre, Ph.D., DABT, CEO, Aravive
Webcast:	Conference attendees can check the schedule for more details or reach out to their William Blair salesperson.

A replay of the session will be available for 7 days following the event through the Aravive Events & Presentations section of the website https://ir.aravive.com/events-and-presentations.

About Aravive
Aravive, Inc. is a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease. Our lead product candidate, batiraxcept (formerly AVB-500), is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the U.S. FDA and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase 3 trial in platinum resistant ovarian cancer (NCT04729608), a Phase 1b/2 trial in clear cell renal cell carcinoma (NCT04300140), and a Phase 1b/2 trial in pancreatic adenocarcinoma (NCT04983407). The Company is based in Houston, Texas and received a Product Development Award from the Cancer Prevention & Research Institute of Texas (CPRIT) in 2016. Additional information at www.aravive.com.

Investor Relations Contact:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
cdavis@lifesciadvisors.com

FAQ

Who is participating in the fireside chat at the William Blair Innovator Series?

Gail McIntyre, Ph.D., DABT, the CEO of Aravive, Inc.

When and where will the event be held?

The event will be held virtually on July 18, 2023.

Will there be a replay of the session available?

Yes, a replay of the session will be available for 7 days following the event.

Where can I find the replay of the session?

The replay will be available through the Aravive Events & Presentations section of their website.